Which Patient in the Neonatal Intensive Care Unit should Receive Antifungal Prophylaxis Therapy?

Area of Science:

• Neonatal Medicine
• Infectious Diseases
• Pharmacology

Background:

• Extremely preterm infants face significant risks of mortality and neurodevelopmental issues due to invasive Candida infections.
• Invasive candidiasis rates in Neonatal Intensive Care Units (NICUs) can be moderate (5-10%) or high (≥10%), necessitating preventative measures.
• Prophylactic antifungal therapy is a proven strategy to decrease Candida colonization and invasive infections in high-risk neonates.

Purpose of the Study:

• To evaluate the efficacy and safety of prophylactic antifungal therapy in extremely preterm infants.
• To determine the optimal timing and patient population for initiating antifungal prophylaxis.
• To assess the impact of prophylaxis on mortality, morbidity, and the development of fungal resistance.

Main Methods:

• Review of studies on prophylactic antifungal use in extremely low birth weight (ELBW) infants and those below 27 weeks gestation.
• Analysis of data on fluconazole prophylaxis, including short-term and long-term safety profiles.
• Examination of NICU-specific candidiasis rates to guide prophylactic treatment initiation.

Main Results:

• Prophylactic antifungal therapy significantly reduces colonization and invasive candidemia in high-risk preterm infants.
• Fluconazole prophylaxis has demonstrated short-term and long-term safety without inducing fungal resistance.
• Early initiation of prophylaxis (within 48-72 hours of birth) is crucial for eligible infants.

Conclusions:

• Antifungal prophylaxis, particularly fluconazole, is a beneficial intervention for extremely preterm infants at risk of invasive Candida infections.
• Implementing prophylactic antifungal strategies can lower mortality rates and improve overall outcomes in vulnerable neonatal populations.
• Targeted prophylaxis based on infant risk factors and NICU candidiasis rates is essential for effective infection control.